Article thumbnail

The Cost-effectiveness of Screening for Chronic Hepatitis B Infection in the United States

By Mark H. Eckman, Tiffany E. Kaiser and Kenneth E. Sherman

Abstract

Current CDC/USPHS screening threshold of 2% for prevalence of chronic HBV is “costeffective.” Screening US adults in lower prevalence populations (eg, as low as 0.3%) also is likely to be cost-effective, suggesting that current health policy should be reconsidered

Topics: Articles and Commentaries
Publisher: Oxford University Press
OAI identifier: oai:pubmedcentral.nih.gov:3097367
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)

  • To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

    Suggested articles